Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Z3XJ
|
||||
| Former ID |
DNC007081
|
||||
| Drug Name |
3-(2-(naphthalen-2-ylmethyl)phenyl)acrylic acid
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [528393] | ||
| Formula |
C20H16O2
|
||||
| Canonical SMILES |
C1=CC=C2C=C(C=CC2=C1)CC3=CC=CC=C3C=CC(=O)O
|
||||
| InChI |
1S/C20H16O2/c21-20(22)12-11-17-6-2-4-8-19(17)14-15-9-10-16-5-1-3-7-18(16)13-15/h1-13H,14H2,(H,21,22)/b12-11+
|
||||
| InChIKey |
MOLQZQYMXCCLHS-VAWYXSNFSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Prostaglandin E2 receptor, EP4 subtype | Target Info | Inhibitor | [528393] | |
| Prostaglandin E2 receptor EP3 subtype | Target Info | Inhibitor | [528393] | ||
| Prostaglandin E2receptor, EP2 subtype | Target Info | Inhibitor | [528393] | ||
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Inflammatory mediator regulation of TRP channels | |||||
| Renin secretion | |||||
| Pathways in cancerhsa04020:Calcium signaling pathway | |||||
| cAMP signaling pathway | |||||
| Regulation of lipolysis in adipocytes | |||||
| Pathways in cancerhsa04024:cAMP signaling pathway | |||||
| Pathways in cancer | |||||
| References | |||||